Impax Laboratories Inc Stock as Institutional Investors Exit

May 16, 2018 - By Louis Casey

Impax Laboratories, Inc. (NASDAQ:IPXL) Logo

Sentiment for Impax Laboratories Inc (NASDAQ:IPXL)

Impax Laboratories Inc (NASDAQ:IPXL) institutional sentiment decreased to 1.26 in Q4 2017. Its down -0.49, from 1.75 in 2017Q3. The ratio dropped, as 91 hedge funds increased or started new holdings, while 72 trimmed and sold positions in Impax Laboratories Inc. The hedge funds in our partner’s database now have: 73.13 million shares, up from 65.84 million shares in 2017Q3. Also, the number of hedge funds holding Impax Laboratories Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 27 Reduced: 45 Increased: 55 New Position: 36.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.31 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

It closed at $18.3 lastly. It is up 51.97% since May 16, 2017 and is uptrending. It has outperformed by 40.42% the S&P500.

Fosun International Ltd holds 5.63% of its portfolio in Impax Laboratories, Inc. for 3.85 million shares. Maverick Capital Ltd owns 7.33 million shares or 1.54% of their US portfolio. Moreover, Hussman Strategic Advisors Inc. has 0.48% invested in the company for 100,000 shares. The California-based Tcw Group Inc has invested 0.27% in the stock. Menta Capital Llc, a California-based fund reported 60,385 shares.

Impax Laboratories, Inc. (NASDAQ:IPXL) Ratings Coverage

Ratings analysis reveals 38% of Impax Laboratories’s analysts are positive. Out of 8 Wall Street analysts rating Impax Laboratories, 3 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $18.0 while the high is $27. The stock’s average target of $21.38 is 16.83% above today’s ($18.3) share price. IPXL was included in 8 notes of analysts from December 12, 2017. Cowen & Co maintained the stock with “Hold” rating in Thursday, March 1 report. The stock has “Hold” rating by RBC Capital Markets on Friday, March 2. On Tuesday, December 12 the stock rating was initiated by Guggenheim with “Hold”. The firm earned “Buy” rating on Tuesday, January 2 by Leerink Swann. BMO Capital Markets maintained it with “Hold” rating and $2000 target in Sunday, April 15 report. Susquehanna maintained Impax Laboratories, Inc. (NASDAQ:IPXL) rating on Tuesday, February 27. Susquehanna has “Hold” rating and $19.0 target.

Impax Laboratories, Inc. (NASDAQ:IPXL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: